| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT04069936 Details | 2022-08-02 Interventional | 2 | 19 | Nivolumab Tadalafil Carcinoma, Non-… Lung Neoplasms Neoplasms Lung Cancer Lung Cancer Met… Lung Cancer, No… NSCLC Non Small Cell … Non Small Cell … Non-small Cell … Non-small Cell … | Resourcing - | |||
| NCT02972294 Details | 2022-08-02 Interventional | 3 | 419 | Ferric Compound… Iron Iron isomaltosi… Tranexamic Acid Fractures, Bone Hip Fractures Anemia Hip Fractures P… | 1year inclusion hold due to PV new fact (Monofer hold for risk revaluation) DSMB Interim
analysis : 1treatment with important transfusion risk reduction/inclusions issues (COVID)/sites
change of practice if study continue=>stop inclusions - | |||
| NCT05451095 Details | 2022-08-01 Interventional | 1 | 0 | Ketamine Healthy | Termination of project - | |||
| NCT05092581 2021-004535-84 Details | 2022-07-29 Interventional | 1 | 2 | Casirivimab and… COVID-19 | Emerging SARS-CoV-2 variants impacting susceptibility to study drug - | |||
| NCT02743598 Details | 2022-07-29 Interventional | 4 | 4 | Liraglutide Diabetes Mellit… Diabetes Mellit… HIV Infections Metabolic Syndr… Overweight Diabetes Mellit… HIV Infection Obesity | Lack of funding and time - | |||
| NCT04953052 Details | 2022-07-28 Interventional | 2 | 0 | Imatinib Mesyla… Acute Lung Inju… COVID-19 Pulmonary Edema Respiratory Dis… Respiratory Dis… Syndrome ARDS Acute Respirato… COVID-19 Acute … Covid19 Pulmonary Oedem… | Number of moderate to severe ARDS patients hospitalised due to COVID19 diminishingly small. Not
expected to recruit required minimum number of patients. - | |||
| NCT04560686 Details | 2022-07-28 Interventional | 2 | 2 | Atezolizumab Carcinoma, Non-… Lung Neoplasms Resectable Lung… Stage I Lung Ca… Stage IA1 Lung … Stage IA2 Lung … Stage IA3 Lung … Stage IB Lung C… Stage II Lung C… Stage IIA Lung … Stage IIB Lung … Stage IIIA Lung… Stage IIIB Lung… | Per PI Request Two participants were consented; one screen failure. The trial was terminated earlier than planned due to an administrative decision taken by the PI/co-PI in collaboration with the study sponsor based on emerging data made available with the investigational agent being tested in other diseases in the perioperative setting. | |||
| NCT01620788 Details | 2022-07-27 Interventional | 3 | - | Hydrochlorothia… Indapamide Losartan Hypertension | Substancial amendment - | |||
| NCT05205759 2021-002612-31 Details | 2022-07-26 Interventional | 3 | 319 | Bamlanivimab Casirivimab and… Sotrovimab COVID-19 | Stop for futility after the onset of the omicron wave - | |||
| NCT03199963 Details | 2022-07-26 Interventional | 3 | 223 | Afimoxifene Tamoxifen Mammographic Br… | Administrative - change in development strategy Other (Not Including Serious) Adverse Events entries are based on number of subject in the intention-to-treat (ITT) population (blinded phase, safety population). Includes all adverse events reported. | |||
| NCT02575339 Details | 2022-07-26 Interventional | 1/2 | 11 | Sorafenib Carcinoma Carcinoma, Hepa… HCC Hepatocellular … Liver Cancer | Funder Decision - | |||
| NCT01963728 Details | 2022-07-26 Interventional | 4 | 2 | Insulin Insulin Glargin… Insulin, Globin… Insulin, Isopha… Isophane Insuli… Isophane insuli… Diabetes Mellit… | Blood sugar status of the enrolled subjects wasn't evaluable - | |||
| NCT04762771 NCT04510038 Details | 2022-07-25 Interventional | 1/2 | 2 | Colchicine COVID-19 Covid19 | Recovery Trial showed no convincing evidence that further recruitment would provide conclusive
proof of worthwhile benefit for the evaluation of Colchicine in patients with Covid-19. The rapid decline in COVID patients and other competing trials did not allowed enrollment of additional subjects. Given the small sample size, the study was terminated. | |||
| NCT04067492 Details | 2022-07-25 Interventional | 2 | 47 | Diclofenac Arthritis, Gout… Gout Gout Attack | In view of the continuing insufficient patient recruitment in the study due to the difficult
epidemiological situation and the need for rational allocation of company resources, as well as
based on the results of the interim analysis. - | |||
| NCT03843853 Details | 2022-07-25 Interventional | 2 | 0 | Bevacizumab Pemetrexed Colorectal Neop… | cooperation terminated - | |||
| NCT02413138 Details | 2022-07-25 Interventional | 2/3 | 41 | Hormones Dwarfism, Pitui… Endocrine Syste… Growth Disorder… Pediatric Growt… | The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not
achieved - | |||
| NCT02793583 Details | 2022-07-21 Interventional | 2/3 | 710 | Bendamustine Hy… Leukemia, Lymph… Lymphoma Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… Diffuse Large B… Follicular Lymp… Mantle Cell Lym… Marginal Zone L… Small Lymphocyt… | Strategic/Business Decision - | |||
| NCT02623439 Details | 2022-07-21 Interventional | 2 | - | Cyclophosphamid… Hematologic Neo… Neoplasms Hematologic Mal… | On hold for toxicitiy - | |||
| NCT00746590 Details | 2022-07-21 Interventional | 2 | 1 | Tretazicar Carcinoma Carcinoma, Hepa… Hepatocellular … | Study terminated prematurely by sponsor for business reason. One patient was enrolled. - | |||
| NCT03912337 Details | 2022-07-20 Interventional | 4 | 29 | Erenumab Migraine Disord… Migraine | Terminated [Study would not complete enrollment target until 2026 with results available in
2027. The information will not be useful at that time.] The study was terminated early due to slow enrollment and the impact of COVID-19 on the work productivity study endpoints, beyond normal operational disruptions. |